Bayer Can Keep Xarelto Profits Earned During Sales Ban
A London court ruled Monday that Bayer can keep the profits it banked from selling blood-thinning treatment Xarelto during an interim sales ban that stopped generic-drugmakers infringing the now-revoked patent....To view the full article, register now.
Already a subscriber? Click here to view full article